Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytoreductive Prostatectomy in Metastatic Prostate Cancer
NCT02458716Phase 1Completed
- Sponsor
- Rutgers University
- Start
- Mar 2015
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Metastatic Prostate Cancer (mPC), sponsored by Rutgers University. Primary endpoint: Rate of major peri-operative complications defined as Clavien-Dindo grade III or higher at 90 days. Started Mar 2015; status: completed.
02
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT02458716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02458716.